Advertisement

Neuroscience and Behavioral Physiology

, Volume 42, Issue 6, pp 575–581 | Cite as

Targeted Inactivation of the Gene Encoding Gamma-Synuclein Affects Anxiety Levels and Investigative Activity in Mice

  • V. S. KokhanEmail author
  • A. V. Bolkunov
  • A. A. Ustiugov
  • G. I. Van’kin
  • T. A. Shelkovnikova
  • O. M. Redkozubova
  • T. V. Strekalova
  • V. L. Buchman
  • N. N. Ninkina
  • S. O. Bachurin
Article
  • 34 Downloads

Gamma (γ) synuclein is a member of the family of synucleins, which are cytoplasmic, predominantly, neuronal, proteins found only in vertebrates. Significant quantities of γ-synuclein are found in the axons and presynaptic terminals of neurons located in brain areas responsible for forming emotions and memory. However, the involvement of γ-synucleins in controlling neuronal and synaptic processes underlying various types of behavior in humans and animals have not yet been studied. We provide the first demonstration that the absence of γ-synuclein increases orientational-investigative activity in a novel context and decreases the level of situational anxiety in animals.

Keywords

γ-synuclein knockout mouse genetically modified animals anxiety behavior 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    V. L. Bukhman, “Synucleins – keys to the mechanisms of neurodegenerative disorders?” Molecule. Biol., 32, 592–597 (1998).Google Scholar
  2. 2.
    N. N. Ninkina and V. L. Bukhman, “Synucleins – to have or not to have?” Genetika, 36, 1487–1492 (2000).PubMedGoogle Scholar
  3. 3.
    A. Abeliovich, Y. Schmitz, I. Farinas, D. Choi-Lundberg, W. H. Ho, P. E. Castillo, N. Shinsky, J. M. Verdugo, M. Armanini, A. Ryan, M. Hynes, H. Phillips, D. Sulzer, and A. Rosenthal, “Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system,” Neuron, 25, 239–252 (2000).PubMedCrossRefGoogle Scholar
  4. 4.
    A. Al-Wandi, N. N. Ninkina, S. Millership, S. J. Williamson, P. A. Jones, and V. L. Buchman, “Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice,” Neurobiol. Aging, 31, 796–804 (2010).PubMedCrossRefGoogle Scholar
  5. 5.
    M. Angrini, J. C. Leslie, and R. A. Shephard, “Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on openfield behavior,” Pharmacol. Biochem. Behav., 59, 387–397 (1998).PubMedCrossRefGoogle Scholar
  6. 6.
    C. Belzung and G. Griebel, “Measuring normal and pathological anxiety-like behaviour in mice: a review,” Behav. Brain Res., 125, 141–149 (2001).PubMedCrossRefGoogle Scholar
  7. 7.
    V. L. Buchman, H. J. Hunter, L. G. Pinõn, J. Thompson, E. M. Privalova, N. N. Ninkina, and A. M. Davies, “Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system,” J. Neurosci., 18, 9335–9341 (1998).PubMedGoogle Scholar
  8. 8.
    V. L. Buchman and N. N. Ninkina, “Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies – is the juice worth the squeeze?” Neurotox. Res., 14, 329–341 (2008).PubMedCrossRefGoogle Scholar
  9. 9.
    M. Carli, C. Prontera, and R. Samanin, “Effect of 5-HT1A agonists on stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolytic-like activity,” Neuropharmacology, 28, 471–476 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    S. Chandra, F. Fornai, H. B. Kwon, U. Yazdani, D. Atasoy, Z. Liu, R. E. Hammer, G. Battaglia, D. C. German, P. Castillo, and T. C. Sudhof, “Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions,” Proc. Natl. Acad. Sci. USA, 101, 14966–14971 (2004).PubMedCrossRefGoogle Scholar
  11. 11.
    F. Curulli, L. De Acetis, and E. Alleva, “Behavioral effects of peripheral interleukin-1 administration in adult CD-1 mice: specific inhibition of the offensive components of intermale agonistic behavior,” Brain Res., 791, 308–312 (1998).CrossRefGoogle Scholar
  12. 12.
    W. Dauer, N. Kholodilov, M. Vila, A. C. Trillat, R. Goodchild, K. E. Larsen, R. Staal, K. Tieu, Y. Schmitz, C. A. Yuan, M. Rocha, V. Jackson-Lewis, S. Hersch, D. Sulzer, S. Przedborski, R. Burke, and R. Hen, “Resistance to alpha-synuclein null mice to the parkinsonian neurotoxin MPTP,” Proc. Natl. Acad. Sci. USA, 99, 14524–14529 (2002).PubMedCrossRefGoogle Scholar
  13. 13.
    K. K. Dev, KI. Hofele, S. Barbieri, V. L. Buchman, and H. van der Putten, “Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease,” Neuropharmacology, 45, 14–44 (2003).PubMedCrossRefGoogle Scholar
  14. 14.
    D. L. Fortin, M. D. Troyer, K. Nakamura, S. Kabo, M. D. Anthony, and R. H. Edwards, “Lipid rafts mediate the synaptic localization of alpha-synuclein,” J. Neurosci., 24, 6715–6723 (2004).PubMedCrossRefGoogle Scholar
  15. 15.
    K. Howard, D. Gershenfeld, P. E. Neumann, C. Mathis, J. N. Crawley, L. I. Xiaohua, and S. M. Paul, “Mapping quantitative trait loci for open-field behavior in mice,” Behav. Genet., 27, 201–210 (1997).CrossRefGoogle Scholar
  16. 16.
    R. G. Lister, “The use of a plus-maze to measure anxiety in the mouse,” Psychopharmacology, 92, 180–185 (1987).PubMedGoogle Scholar
  17. 17.
    P. Malmberg-Aiello, A. Ipponi, A. Bartolini, and W. Schunack, “Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors,” Pharmacol. Biochem. Behav., 71, 313–318 (2002).PubMedCrossRefGoogle Scholar
  18. 18.
    J. M. Marques, I. A. Olsson, S. O. Ogren, and K. Dahlborn, “Evaluation of exploration and risk assessment in pre-weaning mice using the novel cage test,” Physiol. Behav., 93, 139–147 (2008).PubMedCrossRefGoogle Scholar
  19. 19.
    A. G. Nasello, C. Machado, J. F. Bastos, and L. F. Felicio, “Sudden darkness induces a high activity-low anxiety state in male and female rats,” Physiol. Behav., 63, 451–454 (1998).PubMedCrossRefGoogle Scholar
  20. 20.
    N. N. Ninkina, M. V. Alimova-Kost, J. W. Paterson, L. Delaney, B. B. Cohen, S. Imreh, N. V. Gnuchev,A. M. Davies, and V. L. Buchman, “Organization, expression and polymorphism of the human persyn gene,” Hum. Mol. Genet., 7, 1417–1424 (1998).PubMedCrossRefGoogle Scholar
  21. 21.
    N. N. Ninkina, K. Papachroni, D. C. Robertson, O. Schmidt, L. Delany, F. O’Neill, F. Court, A. Rosenthal, S. M. Fleetwood-Walker, A. M. Davies, and V. L. Buchman, “Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene,” Mol. Cell. Biol., 23, 8233–8245 (2003).PubMedCrossRefGoogle Scholar
  22. 22.
    N. N. Ninkina, O. Peters, S. Millership, H. Salem, H can der Putten, and V. L. Buchman, “Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein,” Hum. Mol. Genet., 18, 1779–1794 (2009).PubMedCrossRefGoogle Scholar
  23. 23.
    S. Ramboz, R. Oosting, D. A. Amara, H. F. Kung, P. Blier, M. Mendelsohn, J. J. Mann, D. Brunner, and R. Hen, “Serotonin receptor 1A knockout: an animal model of anxiety-related disorder,” Proc. Natl. Acad. Sci. USA, 95, 14476–14481 (1998).PubMedCrossRefGoogle Scholar
  24. 24.
    D. C. Robertson, O. Schmidt, N. N. Ninkina, P. A. Jones, J. Sharkey, and V. L. Buchman, “Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gammasynuclein null mutant mice,” J. Neurochem., 89, 1126–1136 (2004).PubMedCrossRefGoogle Scholar
  25. 25.
    S. L. Senior, N. N. Ninkina, R. Deacon, D. Bannerman, V. L. Buchman, S. J. Cragg, and R. Wade-Martins, “Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein,” Eur. J. Neurosci., 27, 947–957 (2008).PubMedCrossRefGoogle Scholar
  26. 26.
    J. K. Shepherd, S. S. Grewal, A. Fletcher, D. J. Bill, and C. T. Dourish, “Behavioural and pharmacological characterisation of the elevated ‘zero-maze’ as an animal model of anxiety,” Neurosci., 149, 477–486 (2007).CrossRefGoogle Scholar
  27. 27.
    M. G. Spillantini and M. Goedert, “The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy,” Ann. N.Y. Acad. Sci., 920, 16–27 (2000).Google Scholar
  28. 28.
    T. Strekalova, R. Spanagel, O. Dolgov, and D. Bartsch, “Stressinduced hyperlocomotion as a confounding factor in anxiety and depression models in mice,” Behav. Pharmacol., 16, 171–180 (2005).PubMedCrossRefGoogle Scholar
  29. 29.
    S. Totterdell and G. E. Meredith, “Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain,” Neurosci., 135, 907–913 (2005).CrossRefGoogle Scholar
  30. 30.
    S. Yu, K. Ueda, and P. Chan, “Alpha-synuclein and dopamine metabolism,” Mol. Neurobiol., 31, 243–254 (2005).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • V. S. Kokhan
    • 1
    Email author
  • A. V. Bolkunov
    • 1
  • A. A. Ustiugov
    • 1
  • G. I. Van’kin
    • 1
  • T. A. Shelkovnikova
    • 1
  • O. M. Redkozubova
    • 1
  • T. V. Strekalova
    • 1
  • V. L. Buchman
    • 2
  • N. N. Ninkina
    • 1
    • 2
  • S. O. Bachurin
    • 1
  1. 1.Institute of Physiologically Active Substances, Russian Academy of SciencesChernogolovkaRussia
  2. 2.Cardiff UniversityCardiffUK

Personalised recommendations